Sign In
Buy AXDX
$0.0340
+0 (+0%)
At Close: Aug 12, 2025
Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
09:00am, Thursday, 08'th May 2025
TUCSON, Ariz. , May 8, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate" or the Company") today announced that it has voluntarily initiated a Chapter 11 restructuring pro
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
01:52pm, Friday, 21'st Mar 2025
TUCSON, Ariz. , March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerat
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results
08:30am, Friday, 21'st Mar 2025
TUCSON, Ariz. , March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024.
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results
04:05pm, Friday, 10'th Jan 2025
TUCSON, Ariz. , Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes an
Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript
11:58pm, Friday, 08'th Nov 2024
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and C
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
06:41pm, Thursday, 07'th Nov 2024
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.92 per share a year ago.
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results
04:05pm, Thursday, 07'th Nov 2024
TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024.
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results
04:30pm, Friday, 25'th Oct 2024
TUCSON, Ariz. , Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m.
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
01:16pm, Tuesday, 01'st Oct 2024
AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
09:15am, Monday, 30'th Sep 2024
An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from posit
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
11:06am, Wednesday, 14'th Aug 2024
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript
06:55pm, Saturday, 10'th Aug 2024
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and CEO
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
06:46pm, Thursday, 08'th Aug 2024
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $2.36 per share a year ago.
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
04:05pm, Thursday, 08'th Aug 2024
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024.
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial
04:00pm, Thursday, 08'th Aug 2024
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre
